Hybrid Nitric Oxide Donor and its Carrier for the Treatment of Peripheral Arterial Diseases

Duong Q. Le, Aneetta E. Kuriakose, Dat X. Nguyen, Kytai T. Nguyen, Suchismita Acharya

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Nitric oxide (NO) has been known to promote physiological angiogenesis to treat peripheral arterial diseases (PAD) by increasing the vascular endothelial growth factor (VEGF) level in endothelial cells (ECs) and preventing platelet adherence and leukocyte chemotaxis. However, the ongoing ischemic event during peripheral ischemia produces superoxide and diminishes the NO bioavailability by forming toxic peroxynitrite anion. Here we disclose an efficacious hybrid molecule 4-(5-Amino-1,2,3-oxadiazol-3-yl)-2,2,6,6-tetramethyl-1-piperidinol (SA-2) containing both antioxidant and NO donor functionalities that provide a therapeutic level of NO necessary to promote angiogenesis and to protect ECs against hydrogen peroxide-induced oxidative stress. Compound SA-2 scavenged reactive oxygen species, inhibited proliferation and migration of smooth muscle cells (SMCs) and promoted the tube formation from ECs. Copolymer poly(lactic-co-glycolic acid) (PLGA) nanoparticles loaded with SA-2 provided a sustained release of NO over days, improved aqueous stability in serum, protected ECs against oxidative stress, and enhanced angiogenesis under stress conditions as compared to that of the control in the in vitro matrigel tube formation assay. These results indicated the potential use of SA-2 nanoparticles as an alternative therapy to treat PAD.

Original languageEnglish
Article number8692
JournalScientific Reports
Volume7
Issue number1
DOIs
StatePublished - 1 Dec 2017

Fingerprint Dive into the research topics of 'Hybrid Nitric Oxide Donor and its Carrier for the Treatment of Peripheral Arterial Diseases'. Together they form a unique fingerprint.

  • Cite this